APAC Breast Cancer Therapeutics Market Discussed in Topical GBI Research Study Now Available at MarketPublishers.com15 Mar 2016 • by Natalie Aster
LONDON – There have been all-embracing changes in the breast cancer marketplace over the last 4 decades, especially with respect to the use of targeted therapies, which has grown considerably. Going forward, the market is poised to be driven by a set of new drug approvals and a hike in the adoption of top-scale targeted therapies. Nonetheless, there is still a significant unmet need for products that can increase the survival rates, slow disease progression, as well as improve the overall response.
Today’s breast cancer market contains novel products, comprising Perjeta (pertuzumab), a targeted therapy; Kadcyla, a antibody-drug conjugate (ADC); and Halaven, a new cytotoxic chemotherapeutic agent. With more than 700 active pipeline molecules under development, the majority of the investigational drug candidates are being assessed for the first-line to second-line therapy of stage IV breast cancer, featuring targeted therapies, novel combination therapies, and new immunotherapies offering high potential, and also chemotherapeutic drug candidates.
Through to 2021, the value of the APAC breast cancer therapeutics market is forecast to increase at a CAGR of 8.5%, from USD 1.9 billion to over USD 3.4 billion. A hike in breast cancer prevalence rates and the growing usage of premium targeted therapies in tandem with approvals of new products will likely contribute to immense market growth in the foreseeable future, in spite of generic sales erosion stemming from patent expiries.
Topical study “Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence” elaborated by GBI Research covers the APAC breast cancer therapeutics marketplace, with a focus on the market of India, China, Australia and Japan.
It gives an understanding of the clinical landscape of breast cancer by examining symptoms, pathophysiology, etiology, epidemiology, diagnosis, and treatments. The report looks into treatment strategies, products, and firms dominating the existing marketed products landscape and also identifies the areas and gaps of unmet needs. It limelights major pipeline trends in molecule type, RoA, MoA, and novelty.
The report uncovers market opportunities and potential risks by evaluating trends in the pertinent clinical trials size, duration, and failure rates by development stage, molecule type, and MoA. It examines late-stage pipeline molecules with high therapeutic potential in breast cancer by analysing data from clinical trials and also multi-scenario product forecasts. A comparison of treatment usage patterns, annual therapy costs, and market growth forecasts is included. Further, the report evaluates the trends in co-development and licensing deals relating to breast cancer products and identifies key strategic consolidations.
Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence
Published: February, 2016
Price: US$ 4,995.00
More reports by the publisher can be found at GBI Research page.